Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Repligen Corporation Common Stock — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.09 (market cap $124.07B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 11× Repligen Corporation Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.79% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| MFG | RGEN | |
|---|---|---|
Market Cap | $124.07B | $11.31B |
Volume | 3,230,414 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $11.45 | $194.57 |
52-Week Low | $6.23 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $34.39T | $11.20B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mizuho Financial Group (MFG) trades at $10.60, up slightly by 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.22 exceeding the $0.17 estimate. Revenue grew to $3.65T in 2025, with a net income margin of 30.42% and a P/E ratio of 14.96, indicating reasonable valuation. Recent news highlights institutional stake adjustments and positive CRA ratings.
MFG presents a mixed outlook; earnings momentum and solid profitability support upside, but bearish technicals and analyst caution (60% hold rating) suggest near-term pressure. Key risks include declining cash flow trends and rising debt-to-asset ratio, while institutional interest and dividend growth potential offer opportunities for long-term investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mizuho Financial Group Inc. Sponosred ADR (Japan)
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
